Want to join the conversation?
Biotechnology company $GILD said that it it has submitted a New Drug Application (NDA) to the FDA for tenofovir alafenamide (TAF) 25 mg, a once-daily drug for treating adults with chronic hepatitis B virus (HBV) infection, a condition of the liver. $GILD plans to submit a regulatory application for TAF in the EU in the 1Q16.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?